{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-010409","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.938472+00:00","generated_at":"2026-05-16T10:48:51.051802+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Larimar Therapeutics reports preliminary cash position of $136.9M as of Dec 31, 2025","bullets":["Preliminary cash, cash equivalents and marketable securities of $136.9M as of Dec 31, 2025, unaudited.","Amount is subject to completion of quarter-end and year-end financial close procedures.","Full year 2025 financial results will be included in the upcoming Form 10-K filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-010409","json":"https://secwatch.observer/filing/0001193125-26-010409.json","markdown":"https://secwatch.observer/filing/0001193125-26-010409.md","text":"https://secwatch.observer/filing/0001193125-26-010409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526010409/0001193125-26-010409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526010409/lrmr-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:48:51.051802+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}